IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Hematologic Malignancy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universitymonoclonal_antibodyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
43 Active assets in the Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid Senti Biosciences | Phase 2 | B |
Venetoclax University of Alabama at Birmingham | Phase 2 | B |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →